论文部分内容阅读
目的介绍18F-FDG的制备,探讨其在肿瘤诊断中的作用。方法149例检查对象行18F-FDG代谢显像,其中正常成人20例,已治疗肿瘤患者129例,观察18F-FDG在正常成人及已治疗肿瘤患者体内摄取情况。结果18F-FDG在肿瘤组织呈高摄取,但在肺部良性病变如肺结核、单发结节摄取多存在假阳性及肝肾组织肿瘤摄取少易出现假阴性,对于膀胱及其周围组织由于放射性本底较高代谢显像不明显。结论18F-FDG代谢显像灵敏度高但特异性差,存在假阳性及假阴性现象,给部分肿瘤诊断造成困难,这个问题的解决有赖于新的特异性正电子显像剂的开发。
Objective To introduce the preparation of 18F-FDG and explore its role in tumor diagnosis. Methods 149 patients underwent 18F-FDG metabolic imaging, including 20 normal adults and 129 treated cancer patients. The uptake of 18F-FDG in normal adults and treated cancer patients was observed. Results 18F-FDG was highly upregulated in tumor tissue, but there was more false positives in lung benign lesions such as pulmonary tuberculosis and single nodules uptake, and fewer false-negative tumors in liver and kidney tissues. For radioactive The end of the higher metabolic imaging is not obvious. Conclusions The 18 F-FDG metabolomic imaging has high sensitivity but poor specificity, and there are false positives and false negatives, making it difficult to diagnose some tumors. The solution to this problem depends on the development of new specific positron-imaging agents.